UNFAIR ADVERTISING OF MEDICINES AS A BIOSAFETY THREAT

Abstract

The article discusses the issue of distribution and prospects for combating unfair advertising of medicines as a threat to biosafety. It was established that the object of the research is social relations arising in the field of biosafety and the implementation of countermeasures against unscrupulous advertising of medicines. The main results of the study consist in the study of the specifics of the issue of the spread of unscrupulous advertising of medicines and its impact on consumers through the lens of the biosafety threat. Markers of detection of false and misleading statements in the advertising of medicinal products were analyzed. Using the example of national (Antimonopoly Committee of Ukraine) and international (U.S. Food and Drug Administration) organizations, the practice of combating unfair advertising is summarized. It was found that the sending of warning letters and notification letters by the authorized body directly to pharmaceutical companies prompts them to stop using false information in a short period of time. Examples of violations of the provisions of the legislation on unfair competition in the field of advertising of medicines are given. The prerequisites, features and impact of the moratorium on the advertising of medicinal products are characterized. New legislative changes related to prescription dispensing of medicines have been tracked. According to the results of the conducted research, it is proposed to expand the powers of national bodies; the advantages and disadvantages of individual legislative changes are emphasized, and ways to solve them are provided.